Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
Sign Up to like & getrecommendations! Published in 2022 at "Drug Testing and Analysis"
DOI: 10.1002/dta.3341
Abstract: Abstract Luspatercept (Reblozyl®) is a newly approved anti‐anemic drug prohibited by the World Anti‐Doping Agency. It promotes erythropoiesis by limiting apoptosis of immature erythroblasts and the risk of misuse by athletes for doping is high.… read more here.
Keywords: volunteers antidoping; administration; healthy volunteers; erythropoiesis stimulating ... See more keywords
The addition of oral iron improves chemotherapy‐induced anemia in patients receiving erythropoiesis‐stimulating agents
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34142
Abstract: Although many studies have shown that supplementation with iron and erythropoiesis‐stimulating agents (ESA) is frequently used for managing chemotherapy‐induced anemia (CIA), optimal combination therapy using these agents together to ameliorate anemia is not well characterized.… read more here.
Keywords: induced anemia; oral iron; chemotherapy induced; erythropoiesis stimulating ... See more keywords
Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5152
Abstract: Erythropoiesis‐stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)‐related anemia, contributing to CKD costs. The study was aimed at investigating direct healthcare costs of CKD patients treated with ESAs and the potential savings… read more here.
Keywords: use; chronic kidney; direct healthcare; erythropoiesis stimulating ... See more keywords
Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-019-01787-6
Abstract: Background A decreased response to erythropoiesis-stimulating agents (ESAs) leads to refractory anemia and worse prognosis in patients with chronic kidney disease. We examined the association between autoantibodies to the erythropoietin receptor (EPOR) and responsiveness to… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; epor antibodies; anti epor ... See more keywords
Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-021-02071-2
Abstract: Recent studies have suggested that erythropoiesis-stimulating agents (ESAs) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis. We conducted a 12-week prospective study in 51 dialysis patients; 13 were treated with recombinant human erythropoietin… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; endothelial progenitor; dialysis patients ... See more keywords
Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients
Sign Up to like & getrecommendations! Published in 2018 at "International Urology and Nephrology"
DOI: 10.1007/s11255-018-2062-z
Abstract: PurposeAnaemia and resistance to erythropoiesis-stimulating agents (ESAs) are common complications in haemodialysis (HD) patients. We investigated the role of hepcidin in the development of anaemia and ESA resistance/hyporesponsiveness and its relation to the plasma levels… read more here.
Keywords: erythropoiesis stimulating; hscrp; resistance; hepcidin ... See more keywords
Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
Sign Up to like & getrecommendations! Published in 2021 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2020.12.022
Abstract: Introduction Several jurisdictions have adopted a more conservative approach to anemia in patients receiving dialysis amid safety concerns from target hemoglobin studies. It is largely unknown if this has contributed to a change in clinical… read more here.
Keywords: clinical outcomes; incident dialysis; erythropoiesis stimulating; patients canada ... See more keywords
[Erythropoiesis stimulating agents: Literature review of uses and indications in advanced oncological and non-oncological disease in the elderly].
Sign Up to like & getrecommendations! Published in 2018 at "Revista espanola de geriatria y gerontologia"
DOI: 10.1016/j.regg.2017.06.009
Abstract: The aim of this article is to review possible indications and controversies about the most frequent uses of ESAs in the treatment of anaemia in elderly patients with oncological and non-oncological diseases. Using PubMed a… read more here.
Keywords: oncological non; erythropoiesis stimulating; consensus; disease ... See more keywords
Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients
Sign Up to like & getrecommendations! Published in 2017 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfw328
Abstract: Background In 2012, new clinical guidelines were introduced for use of erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD) patients, recommending lower haemoglobin (Hb) target levels and thresholds for ESA initiation. These changes resulted in… read more here.
Keywords: initiation; erythropoiesis stimulating; stimulating agents; study ... See more keywords
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15450
Abstract: Erythropoiesis‐stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate‐2/high risk; 52·5% transfusion‐dependent). Anaemia response (AR) rate was 54% and 76% of patients responded… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; myelofibrosis; anaemia ... See more keywords
Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13353
Abstract: Research investigating incident malignancy risk in erythropoiesis‐stimulating agent (ESA) users with chronic kidney disease (CKD) is lacking. We aimed to compare the incident cancer risk between ESA and non‐ESA users with CKD or end‐stage renal… read more here.
Keywords: erythropoiesis stimulating; disease; malignancy; risk ... See more keywords